Cytokinetics Investors Urged to Act as Lead‑Plaintiff Deadline Nears in REMS‑Related Securities Suit

Overview

• The lawsuit, Seidman v. Cytokinetics, Incorporated, No. 25-cv-07923, is pending in the U.S. District Court for the Northern District of California and no class has been certified.
• Investors who bought Cytokinetics shares between December 27, 2023 and May 6, 2025 face a November 17, 2025 deadline to seek lead‑plaintiff status.
• The complaint alleges Cytokinetics submitted its aficamten NDA without a Risk Evaluation and Mitigation Strategy, opting to rely on labeling and voluntary education materials.
• Cytokinetics disclosed on May 1, 2025 that the FDA extended aficamten’s PDUFA date from September 26 to December 26, 2025 to review a REMS, and the stock fell following disclosures on May 2 and May 6.
• Multiple firms, including Rosen, Pomerantz, The Gross Law Firm, ClaimsFiler with Kahn Swick & Foti, Frank R. Cruz, and Faruqi & Faruqi, have issued notices inviting eligible shareholders to participate.